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The heme-regulated inhibitor (HRI) negatively regulates protein synthesis by phosphorylating eukaryotic initiation factor-2α
(eIF2α) thereby inhibiting protein translation. The importance of HRI in regulating hemoglobin synthesis in erythroid cells makes
it an attractive molecular target in need of further characterization. In this work, we have cloned and expressed the canine form of
the HRI kinase. The canine nucleotide sequence has 86%, 82%, and 81% identity to the human, mouse, and rat HRI, respectively.
It was noted that an isoleucine residue in the ATP binding site of human, rat, and mouse HRI is replaced by a valine in the canine
kinase. The expression of canine HRI protein by in vitro translation using wheat germ lysate or in Sf9 cells using a baculovirus
expression system was increased by the addition of hemin. Following puriﬁcation, the canine protein was found to be 72kD and
showedkinaseactivitydeterminedbyitsabilitytophosphorylateasyntheticpeptidesubstrate.Quercetin,akinaseinhibitorknown
to inhibit mouse and human HRI, inhibits canine HRI in a concentration-dependent manner. Additionally, quercetin is able to
increase de novo protein synthesis in canine reticulocytes. We conclude that the canine is a suitable model species for studying the
role of HRI in erythropoiesis.
Copyright © 2009 Kimon C. Kanelakis et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Heme-regulated inhibitor (HRI) is an eIF2α kinase, which
belongs to the eIF2α kinase subfamily [1] that includes the
double-stranded RNA-dependent eIF2α kinase (PKR), the
general control of nitrogen metabolism kinase (GCN2), and
them endoplasmic reticulum resident kinase, PKR-related
kinase (PERK), which is identical to the enzyme pancreatic
eIF2α kinase (PEK) that is highly expressed in pancreas [2].
Sequence comparison between HRI and other eIF2α kinases
revealsthattheeIF2αkinasessharesomedegreeofhomology
in their kinase catalytic domains. However, between the N-
and C-lobes HRI has a distinct kinase insert that contains a
heme binding site [3]. Kinase activity of HRI is modulated
by binding of heme to the heme-binding domains located at
its kinase insert and the amino terminus. As an eIF2α kinase,
HRI speciﬁcally phosphorylates eIF2α at residue Serine 51
[4], blocking GTP exchange required for the recycling of
eIF2, and thus inhibits protein synthesis [5]. Because HRI
is predominantly expressed in erythroid cells, HRI exerts its
kinase activity to regulate the synthesis of hemoglobin [6].
Phenotypic changes in HRI knockout mice show that
HRI is nonessential, but plays an important regulatory role
by dictating hemoglobin synthesis in erythroid cells [1].
Notably, in the absence of HRI kinase activity, reticulocytes
obtained from HRI-deﬁcient mice had a higher rate of
protein synthesis. The importance of HRI in the patho-
physiology of heme-deﬁciency disorders such as anemia of
iron deﬁciency, protoporphyria, and β-thalassemia has been
recently shown in animal models [7].
Interestingly, HRI does not exist in yeast, Drosophila
melanogaster,a n dC. elegans [5, 8]. It is postulated that HRI
has evolved during the development of the circulation to
meet the increasing demand for oxygen in larger organisms.2 Advances in Hematology
Alignment of the amino acids of HRI from human, mouse,
rat, and rabbit [8] reveals that HRI is conserved throughout
evolution among these mammals with approximately 77%
identity and 83% homology. Because of the importance of
HRI in regulating hemoglobin synthesis in mammals, we
sought to evaluate the feasibility of using the canine as a
model for studying the homeostasis of erythropoiesis. The
canine HRI was cloned, expressed by in vitro transcription
and translation in wheat germ lysate and also in baculovirus
protein expression system and then compared to the murine
and human HRI proteins by its functional activity and
inhibition by a kinase inhibitor. Additionally, the function of
HRI on protein synthesis was evaluated in canine blood with
the kinase inhibitor, quercetin.
2.MaterialandMethods
2.1. Tissue Isolation and Total RNA Preparation. All pro-
cedures were performed according to the internationally
acceptedguidelinesforthecareanduseoflaboratoryanimals
in research and were approved by the local International
Animal Care and Use Committee. Canine spleen was col-
lected and RNA stabilization was achieved by submersion of
tissueinRNAlater (Ambion,Milan,Italy).TotalcellularRNA
(tc-RNA) from spleen was extracted using the RNeasy kit
following manufacturer’s instructions (Qiagen, Chatsworth,
Calif, USA).
2.2. Cloning of Canine HRI cDNA. Reverse transcription
(RT) reactions on human (Clontech, Mountain View, Calif,
USA) and canine tc-RNA were performed in a 20μLr e a c t i o n
mixture containing 10mM Tris-HCl (pH 8.4), 50mM KCl,
5mMMgCl 2, 500μM dNTP, 1.25μMo fo l i g o ( d T )p r i m e r ,
5μg tc-RNA, 40U of RNase inhibitor, 2U of RNaseH,
and 50U of reverse transcriptase II (Invitrogen, Carlsbad,
Calif, USA). The RT reactions were performed under the
following conditions: 90 minutes at 42oC, 10 minutes
at 70oC, followed by 20 minutes at 37oC. The resulting
cDNA samples (1μL) were used for PCR ampliﬁcation with
the addition of 45μL of Supermix (Invitrogen, Carlsbad,
Calif, USA) containing 2.2U of Taq DNA polymerase (a
mixture of recombinant Taq DNA polymerase and DNA
polymerase from pyrococcus species GB-D) in 66mM
Tris-SO4 (pH 9.1 at 25oC), 19.8mM (NH4)2SO4,2 . 2 m M
MgSO4, 220μM dGTP, 220μM dATP, 220 μM dTTP, 220
μM dCTP, with stabilizers and 20μMo fs e n s e[ 5  -AACGTT
GAATTCGCCACCATGCTGGGGGGCAGCTCCGGT-3 ]
and antisense primers [5 -AACGTT GCGGCCGCTTAAGG
CAGGACGGGCACAGTC-3 ]. Oligonucleotide primers
were designed to be homologous to the corresponding
region of the human HRI (GenBank Accession Number:
NM 014413). The cDNA fragments were ampliﬁed by PCR
under the following conditions: 30s at 94oC for 1 cycle,
followed by 94oC for 30 seconds, 30 seconds at 60oC, 72oC
for 3 minutes for 30 cycles.
2.3. Cloning of Canine HRI cDNA into Expression Vectors.
Two chimeric oligonucleotide primers (described earlier)
were synthesized to facilitate the sub-cloning step (Allele
B i o t e c h ,S a nD i e g o ,C a l i f ,U S A ) .T h ec h i m e r i c5   primer
included three adjacent upstream nucleotides; 6 random
bp followed by a 6bp EcoRI restriction enzyme sequence
and a 6bp Kozak sequence leading to the 21 nucleotides
complementary to the canine HRI cDNA sequence. The
chimeric 3  primer included 6 random bp followed by a 6bp
NotI restriction enzyme sequence and 22bp complementary
to the canine HRI cDNA sequence. PCR with the above 2
chimeric primers resulted in a 1925bp product, consisting
of full length HRI and the sequences corresponding to the
chimeric primers.
2.4. Sequencing. Recombinant double-stranded plasmids
containing the 1893bp full-length HRI cDNA insert
served as templates for cycle sequencing with speciﬁc
forward and reverse primers and ﬂuorescence-based
dideoxynucleotides, using the dideoxy-terminator cycle
sequencing kit (Perkin Elmer, Applied Biosystems,
Foster City, Calif, USA). HRI cDNA sequences were
determined by the use of a DNA Sequencer (ABI Model
373, Applied Biosystems). Canine HRI cDNA sequences
were validated by sequencing cDNA products from three
separate RT-PCR reactions, primers were for the forward
reaction: 5 -ATCTGATGTCCCAGCAGAACTCCA-3 ,5  -
GATACGGAAGAGTGTACAAGGTCA-3 ,5  -AGGATC
CGACTATGACGCC-3 ,a n d5  -TGCACATCCAGATGCAG
CTGTGT-3 , and for the reverse:, 5 - GAG CTC TAG
CAGGATCACACCC-3 ,5  -GATCTTGTGCATGGGTCA
CGTGAA-3 ,5  -GCTGGGACATCAGATTCATCATACT-3 ,
(all primers purchased from Allele Biotech).
2.5. Preparation of Recombinant HRI Baculovirus and Expres-
sion of Canine HRI Protein in Sf9 Cells. Expression of canine
HRI protein (cHRI) in Sf9 cells was achieved using the
protocol from a commercially available Bac-n-Bac transfec-
tion kit (Invitrogen). The pFastBac transfer vector, in which
the canine HRI cDNA was inserted, was transformed into
DH10Bac competent cells containing bacmid DNA and a
helper plasmid. Cells were incubated on ice for 30 minutes
followed by 60 seconds at 42oCa l l o w e df o rt r a n s p o s i t i o n
of the pFastBac-cHRI plasmid with the bacmid catalyzed by
the transposition sequences on the helper plasmid. Colonies
containingrecombinantbacmidswereidentiﬁedbyselection
ofblue/whitecoloniescausedbydisruptionofthelacZαgene
following the cHRI cDNA insertion.
The bacmid DNA was isolated and then transfected into
Sf9 cells to make recombinant baculovirus as previously
described [9]. Sf9 cells were grown in Sf-900 II serum-free
medium in suspension cultures with continuous shaking
(150rpm). Cultures were infected in log phase of growth
with recombinant baculovirus at the multiplicity of infection
of 3.0. Cells were harvested after 48 hours of infection,
washed in phosphate buﬀered saline solution, resuspended
in 1 volume of buﬀer (10 mM Hepes, pH 7.5, 300 mM NaCl,
5m MM g C l 2, 10% glycerol) containing protease inhibitor
mixture, and ruptured by sonication. The lysate was thenAdvances in Hematology 3
centrifuged at 17,000 ×gf o r2 0m i n u t e sa t4 oC and the
supernatant collected.
2.6. Puriﬁcation of Canine HRI Protein. Canine, mouse, rat
and human HRI proteins were expressed in Sf9 cells and
puriﬁedbyNi-NTAaﬃnitychromatography(Qiagen,Valen-
cia, Calif, USA) according to the manufacturer’s recommen-
dationsanddialyzedinbuﬀer(5mMHepes,pH7.4,100mM
NaCl, 2mM DTT) overnight. The canine HRI protein was
separated by SDS-PAGE and identiﬁed by Western blotting
using a mouse anti-histidine primary antibody at 1:1000
(Clontech, Mountain View, Calif, USA) and a secondary
anti-mouse HRP conjugated antibody at 1:10,000 (Pierce
Biotechnology, Rockford, Ill, USA) followed by enhanced
chemiluminescence using the Amersham Enhanced Chemi-
luminescence Plus Western blotting detection system (GE
Biosciences, Piscataway, NJ, USA).
2.7. Expression of Canine HRI Protein by TNT. The cloned
canine HRI in the pcDNA4 vector was linearized with NotI
and 2.8μg of the linearized DNA was used for transcrip-
tion/translation(TNT).ProteinexpressionofthecanineHRI
was achieved using the cell-free expression kit from Promega
using wheat germ lysate according to the manufacturer’s
protocol. The reaction mix was supplemented with 0.5mM
hemin to increase expression of functional kinase. The [35S]-
canine HRI was immunoprecipitated with an anti-histidine
antibody bound to protein A-sepharose and then separated
on a 4–20% PAGE and visualized by autoradiography.
2.8. Kinase Activity Determination of Puriﬁed Canine
HRI Protein. The puriﬁed canine HRI protein was used
to determine its kinase activity in a nonradioactive,
phosphorylation-dependent, homogeneous assay,
AlphaScreen [10]. Brieﬂy, biotinylated HRI substrate,
Poly-GT (Cisbio International, Bedford, Mass, USA) was
incubated with puriﬁed cHRI kinase for 2 hours at room
temperature, in the presence of 4μMA T P ,a n d5 m M
Mg2+/Mn2+ allowing for substrate phosphorylation by
cHRI. AlphaScreen donor and acceptor beads were then
added to the reaction mix according to the manufacturer’s
protocol (Perkin-Elmer, Waltham, Mass, USA). Kinase
activity was determined by detecting an output signal at
540nm wavelength, with signal intensity being directly
proportional to phosphorylated substrate.
For inhibition studies, quercetin (Sigma Chemicals,
St. Louis, Mo, USA) was incubated with the kinase in
the kinase activity assay as detailed earlier. Inhibition of
phosphorylation by the inhibitor was measured as a decrease
in AlphaScreen signal. The pIC50 values were determined by
ﬁtting a three-parameter logistic function using GraphPad
Prism, version 4.02 (Graph Pad Software, San Diego, Calif,
USA).Dataarepresentedasmean ±SEMoftriplicatevalues.
2.9. Protein Synthesis in Peripheral Canine Blood. Whole
bloodfrombeagleobtainedfromBioreclamation(Hicksville,
NY, USA) was washed twice with ice-cold PBS containing
5mM glucose by centrifuging at 2000rpm for 5minutes at
4◦C to remove platelets and clotting factors and was passed
throughacellstrainer(70μMpor esize,BDBioscienc es,Lex-
ington, Ky, USA) to remove any clots. The blood cell pellet
was then resuspended in pre-warmed (37◦C) methionine-
free DMEM (Hyclone, Logan, Utah, USA) containing 2mM
glutamine and was treated with either vehicle (1% DMSO)
or quercetin in the presence of 0.2 mCi [35S]-methionine
(Amersham Bioscience Inc., Piscataway, NJ, USA) for 4
hours at 37◦C in 50mL centrifuge tubes. The samples were
swirled every 30 minutes to ensure adequate mixing. After
labeling, the cells were transferred to Eppendorf tubes and
washed with ice-cold PBS by centrifugation at 14,000rpm
for 5 minutes at 4◦C. The cell pellets were lysed in 1mL
of PBS containing 1% Triton X-100. To remove free [35S]-
methionine, the lysates were subjected to TCA precipitation
and centrifuged at 14,000rpm for 10 minutes at 4◦C.
Methionine incorporation into protein was determined by
addition of Scintiverse liquid scintillation cocktail and then
the[35S]signalwasmeasuredusingabeta-counter(Beckman
Coulter, Fullerton, Calif, USA).
3. Results
3.1. Cloning and Sequence Comparison of Canine HRI cDNA
with Other Mammalian HRI. To decide which canine tissues
to use for cloning canine HRI cDNA, we performed RT-
PCR for HRI using human liver, kidney, lymph node or
spleen (Clontech, Mountain View, Calif, USA). As shown
in Figure 1(a), HRI was detected in liver, lymph node, and
spleen, but not detected in the kidney. Because previous
reports demonstrated that HRI is predominantly expressed
in erythroid-derived cells [6, 7], we presume that the
presence of peripheral blood in the tissues allowed for the
detection of HRI. Based on the tissue expression results of
the human HRI we decided to clone the canine HRI from
canine spleen.
To clone canine HRI cDNA, we prepared total RNA from
canine spleen followed by ﬁrst strand cDNA synthesis using
oligo(dT) primers (Invitrogen). The resulting cDNA was
used in RT-PCR with cloning primers designed based on
the canine genomic sequence corresponding to the human
HRI sequence. A PCR fragment of the expected 1925bp
was ampliﬁed (Figure 1(b)). The resulting fragment was
sequenced and conﬁrmed to be the canine HRI (GenBank
Accession Number FJ911905), showing 86% identity in
nucleotide sequence to the human, 82% identity to the
mouse and 81% identity to the rat HRI (Figure 1(c)). At the
aminoacidlevelthecanineproteinshows83%identitytothe
human HRI sequence (NM 014413) and 81% to the mouse
(NM 013557) and rat HRI (NM 013223) (Figure 1(d)). As
shown in Figure 1(e), the canine sequence shows only 1
amino acid diﬀerence in the ATP-binding site compared to
the human sequence. The high conservation in the residues
involved in ATP binding between the human, canine and
rodent proteins is consistent with the functional importance
of HRI and its conservation throughout evolution.4 Advances in Hematology
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(a)
1925 bp 
23130
9416
6557
1353
1078
872
2322
2027
Spleen
(b)
Canine ATGCTGGGGGGCAGCTCCGGTGCCCGAGAGCGCGAGGCGGAGGGCGACGGGGCGGAGGCT 60
Human   ATGCAGGGGGGCAACTCCGGGGTCCGCAAGCGCGAAGAGGAGGGCGACGGGGCTGGGGCT 60
Rat     ATGCTGGGGGGCGGCTCCGTGGATGGCGAGCGCGACACGGACGACGACGCGGCGGGGGCG 60
Mouse   ATGCTGGGGGGCAGCTCCGTGGACGGCGAGCGCGACACGGACGACGACGCGGCGGGGGCG 60
**** ******* ***** * * ******* *** * ***** *** * ***
Canine GTGCCTGCGCCTCCTGCCATCGAGTTCCCGGCCGACGGCTCGGACCCCAAGTATGATGAA 120
Human   GTGGCTGCGCCGCCGGCCATCGACTTTCCCGCCGAGGGCCCGGACCCCGAATATGACGAA 120
Rat     GTGGCCGCGCCTCCTGCCATCGACTTCCCCGCAGAGGTGTCGGACCCCAAGTATGATGAG 120
Mouse   GTGGCCGCGCCTCCTGCCATCGACTTCCCCGCAGAGGTGTCGGACCCCAAGTATGATGAG 120
*** * ***** ** ******** ** ** ** ** * ******** * ***** **
Canine TCTGATGTCCCAGCAGAACTCCAAGTATTAAAAGGACCCCTACAACAGCCGACTTTCCCT 180
Human   TCTGATGTTCCAGCAGAAATCCAGGTGTTAAAAGAACCCCTACAACAGCCAACCTTCCCT 180
Rat     TCCGATGTCCCAGCAGAGCTCCAAGTGTTCAAAGAGCCCTTGCAGCAGCCCACGTTCCCT 180
Mouse   TCCGATGTCCCCGCAGAGCTCCAAGTGTTAAAAGAGCCCCTACAGCAGCCCACGTTCCCT 180
** ***** ** ***** **** ** ** **** *** * ** ***** ** ******
Canine TTTGCAGTTGCAAACCAACTCTTGCTCGTCTCTTTGCTGGAGCACTTGAGCCATGTGCAT 240
Human   TTTGCAGTTGCAAACCAACTCTTGCTGGTTTCTTTGCTGGAGCACTTGAGCCACGTGCAT 240
Rat     TTCTTAGTGGCAAACCAGCTGCTGCTGGTCTCCTTGCTGGAACACTTGAGCCATGTGCAC 240
Mouse   TTCCTGGTGGCAAACCAGCTGCTGCTCGTCTCCTTACTGGAACACTTGAGCCATGTGCAC 240
** ** ******** ** **** ** ** ** ***** *********** *****
Canine GAACCAAACCCGCTCCGTTCAAGACAGGTGTTTAAATTGCTTTGCCAGACCTTTATCAAA 300
Human   GAACCAAACCCACTTCGTTCAAGACAGGTGTTTAAGCTACTTTGCCAGACGTTTATCAAA 300
Rat     GAGCCGAACCCACTTCACTCAAAACAGGTCTTTAAATTACTGTGCCAGACTTTTATCAAG 300
Mouse   GAGCCAAACCCGCTCCACTCCAAACAGGTGTTTAAATTACTGTGCCAGACTTTTATCAAG 300
** ** ***** ** * ** * ****** ***** * ** ******** ********
Canine ATGGGGCTGCTGTCTTCTTTCACCTGTAGTGATGAGTTTAGCTCATTGAGGCTACATCAC 360
Human   ATGGGGCTGCTGTCTTCTTTCACTTGTAGTGACGAGTTTAGCTCATTGAGACTACATCAC 360
Rat     ATGGGGCTGCTCTCTTCCTTTACCTGCAGCGATGAGTTCAGCTCCCTGAGACTCCACCAC 360
Mouse   ATGGGGCTGCTCTCTTCCTTTACCTGCAGTGATGAGTTTAGCTCTCTGAGACTCCACCAC 360
*********** ***** ** ** ** ** ** ***** ***** **** ** ** ***
Canine AACAGAGCTATTACTCATTTAATGAGATCTGCTAAAGAGAGAGTTCGTCAGGATCCTTGT 420
Human   AACAGAGCTATTACTCACTTAATGAGGTCTGCTAAAGAGAGAGTTCGTCAGGATCCTTGT 420
Rat     AACAGAGCCATCACTCATTTAATGAGGTCTGCCAAGGAGAGAGTCCGTCAGGATCCTTGT 420
Mouse   AACAGAGCCATCACTCATTTAATGAGGTCTGCCAAAGAGAGAGTCCGTCAGGATCCTTGT 420
******** ** ***** ******** ***** ** ******** ***************
Canine GAAGATAATTCTCATACCCAGAAGATCAGATCAAGGGAAATAGCCTTTGAAGCACAGACT 480
Human   GAGGATATTTCTCGTATCCAGAAAATCAGATCAAGGGAAGTAGCCTTGGAAGCACAAACT 480
Rat     CAAGATAATTCTTACATGCAGAAAATCAGATCCAGGGAGATAGCTCTCGAAGCACAGACT 480
Mouse   CAAGATAATTCTTACATGCAGAAAATCAGATCCAGAGAGATAGCCTTCGAAGCACAAACG 480
* **** **** * ***** ******** ** ** **** * ******** **
Canine TCACGTTACCTAAATGAATTTGAAGAGCTTGCTGTCTTAGGCAAAGGTGGATACGGAAGA 540
Human   TCACGTTACTTAAATGAATTTGAAGAACTTGCCATCTTAGGAAAAGGTGGATACGGAAGA 540
Rat     TCACGCTACTTAAATGAATTTGAAGAGCTCGCCATCTTAGGAAAAGGCGGATATGGAAGA 540
Mouse   TCACGCTACTTAAATGAATTTGAAGAGCTTGCCATCTTAGGGAAAGGAGGATATGGAAGA 540
***** *** **************** ** ** ******* ***** ***** ******
Canine GTGTACAAGGTCAGGAATAAATTAGATGGTCAGTATTATGCAATTAAAAAAATCCTGATT 600
Human   GTATACAAGGTCAGGAATAAATTAGATGGTCAGTATTATGCAATAAAAAAAATCCTGATT 600
Rat     GTTTACAAGGTCCGGAACAAATTAGATGGTCAGCATTATGCAATTAAGAAAATCCTGATT 600
Mouse   GTTTACAAGGTCCGGAACAAATTAGATGGTCAGCATTATGCAATTAAGAAAATCCTGATT 600
** ********* **** *************** ********** ** ************
Canine AATGGTGCAACTAAAACAGATTGTATGAAGGTACTACGGGAAGTGAAGGTGCTGGCAGGC 660
Human   AAGGGTGCAACTAAAACAGTTTGCATGAAGGTCCTACGGGAAGTGAAGGTGCTGGCAGGT 660
Rat     AAGAGTGCAACTAAAACGGATTGTATGAAGGTGCTACGGGAAGTGAAGGTTCTGGCAGGC 660
Mouse   AAGAGCGCAACTAAAACAGATTGTATGAAGGTGCTACGGGAAGTGAAGGTTCTGGCAGGT 660
** * *********** * *** ******** ***************** ********
Canine CTTCAGCATCCTAACATAGTAGGCTATCACACTGCTTGGATAGAACATGTTCACGTGACC 720
Human   CTTCAGCACCCCAATATTGTTGGCTATCACACCGCGTGGATAGAACATGTTCATGTGATT 720
Rat     CTCCAGCACCCCAATATCGTTGGCTACCACACTGCATGGATAGAGCACGTTCACGTGCTT 720
Mouse   CTCCAGCATCCCAATATTGTTGGCTACCACACTGCGTGGATAGAACATGTTCATGTGGTT 720
** ***** ** ** ** ** ***** ***** ** ******** ** ***** ***
Canine CATGCACAAG- - -ATCGAATTTCTATTCAGCTGCCATCTCTGGAAGTGATCTCTGACGAG 777
Human   CAGCCACGAGCAGACAGAGCTGCCATTGAGTTGCCATCTCTGGAAGTGCTCTCCGACCAG 780
Rat     CAGCCACAAG- - -ACAGAGTTCCCATTCAACTGCCCTCTCTTGAAGTGTTGTCAGAGCAT 777
Mouse   CAGCCACAAG- - -ACAGAGTTCCGATTCAACTGCCCTCTCTCGAAGTGCTGTCGGAGCAG 777
** *** ** * ** * * *** * **** ***** ****** * ** ** *
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Canine TCACCCAGTTTTCTCCAAAGAAATGGTTTGGCTGATTTGCCTTCCAGCTCAATTATTGAA
Human   TCGACCCTGGAGCTCCAGGAAAATGGCTTGGCTGGTTTGTCTGCCAGTTCAATTGTGGAA
Rat     TCGTCCATTGAGCTCCAAGAAGATGGCTTGAACGAGTCGCCTCTCAGACCAGTTGTCAAG
Mouse   TCGTCCATTGAGCTCCAAGAAGACGGCTTGACTGATTTGTCCGTCAGACCAGTTGTCAGG
** ** ***** * * ** *** * * * * *** ** ** *
Canine CATCAGCTGCCACTTAGGCATCATTCCGACTTAGAAGAGAATTTCACATCCACTGGGGAA
Human   CAGCAGCTGCCACTCAGGCGTAATTCCCACCTAGAGGAGAGTTTCACATCCACCGAAGAA
Rat     CACCAGCTGCCGCTGGGGCATAGCTCAGACGTGGAAGGGAATTTTACCTCCACGGATGAG
Mouse   CATCAGCTGCCGCTGGGGCATAGCTCGGAATTGGAAGGGAATTTTACATCCACGGATGAG
** ******** ** *** * ** * * ** * ** *** ** ***** * **
Canine TCTTCTGAA- - -AACTTAAGTTTGTTGGGGCAGACAGAGGTGCAGTACCACTTGATGCTG
Human   TCTTCCGAAGAAAATGTCAACTTTTTGGGTCAGACAGAGGCACAGTACCACCTGATGCTG
Rat     TCTTCTGAAGACAATTTGAACCTGCTGGGGCAGACAGAGGCGCGGTACCACCTGATGCTG
Mouse   TCTTCTGAAGGCAACTTGAACCTGCTGGGGCAGACGGAGGTTCGGTACCACCTGATGTTG
***** *** ** * * * **** ***** **** * ******* ***** **
Canine CACATCCAGATGCAGCTGTGTGAGCTCTCCCTGTGGGACTGGATAGTGGAGAGAAACCAG
Human   CACATCCAGATGCAGCTGTGTGAGCTCTCGCTGTGGGATTGGATAGTCGAGAGAAACAAG
Rat     CACATCCAGATGCAGCTGTGTGAGCTCTCCCTGTGGGACTGGATAGCTGAGAGGAACAAG
Mouse   CACATCCAGATGCAGCTGTGTGAGCTCTCCCTGTGGGACTGGATAACTGAGAGGAACAAG
***************************** ******** ****** ***** *** **
Canine CGGGGTCGGCAGTATGTGGACGAATCTGCATGTCCTTATGTCATGGCCAGTGTTGCAACA
Human   CGGGGCCGGGAGTATGTGGACGAGTCTGCCTGTCCTTATGTTATGGCCAATGTTGCAACA
Rat     CGGAGCCGGAAGTGCGTGGATGAAGCAGCTTGTCCCTATGTTATGGCCAGTGTTGCAACA
Mouse   CGGAGCCGGGAGTATGTGGACGAAGCTGCTTGTCCCTATGTTATGGCCAGTGTTGCAACA
*** * *** *** ***** ** * ** ***** ***** ******* **********
Canine AAGATTTTTCAAGAACTGGTGGAAGGTGTATTTTACATACATAACATGGGAATCGTACAC
Human   AAAATTTTTCAAGAATTGGTAGAAGGTGTGTTTTACATACATAACATGGGAATTGTGCAC
Rat     AAGATTTTTCAAGAACTGGTGGAAGGTGTCTTTTACATACATAACATGGGCATCGTCCAC
Mouse   AAAATTTTTCAAGAATTGGTGGAAGGTGTCTTTTACATACATAACATGGGCATTGTCCAC
** ************ **** ******** ******************** ** ** ***
Canine AGAGATCTGAAGCCAAGAAATATTTTTCTTCATGGCCCTGATCAGCAAGTAAAAATAGGA
Human   CGAGATCTGAAGCCAAGAAATATTTTTCTTCATGGCCCTGATCAGCAAGTAAAAATAGGA
Rat     AGAGATCTGAAGCCTAGAAATATTTTTCTTCATGGTCCTGATCAACAAGTGAAAATAGGA
Mouse   AGAGATCTGAAGCCTAGAAATATTTTTCTTCATGGCCCTGATCAGCAAGTAAAAATAGGA
************* ******************** ******** ***** *********
Canine GACTTTGGTCTGGCCTGCACAGACATCATTCAAAAGAACACAGACTGGATCGGTAGAGAT
Human   GACTTTGGTCTGGCCTGCACAGACATCCTACAGAAGAACACAGACTGGACCAACAGAAAC
Rat     GACTTTGGTCTGGCCTGTGCAGACATCATTCAGAAGAGCGCAGATTGGACCAACAGAAAC
Mouse   GACTTTGGTCTGGCCTGTGCAGACATCATCCAGAA - - - TGCAGACTGGACCAACAGAAAT
***************** ******** * ** ** **** **** * *** *
Canine GGGAAGAGGCCACCCACACACACTTCCAGAGTGGGTACTTGTCTATACGCTTCACCTGAG
Human   GGGAAGAGAACACCAACACATACGTCCAGAGTGGGTACTTGTCTGTACGCTTCACCCGAA
Rat     GGGAAAGGAACGCCGACACACACGTCCCGAGTGGGGACTTGTCTCTACGCGTCACCTGAG
Mouse   GGGAAAGGAACACGGACACACACATCCAGAGTGGGGACTTGTCTCTACGCATCACCGGAA
***** * * * ***** ** *** ******* ******** ***** ***** **
Canine CAGTTGGAAGGATCCGACTATGACGCCAAGTCAGATATGTACAGCTTGGGTGTGATCCTG
Human   CAGTTGGAAGGATCTGAGTATGATGCCAAGTCAGATATGTACAGCTTGGGTGTGGTCCTG
Rat     CAGTTGGAAGGATCCGAGTATGATGCCAAGTCTGATATGTACAGCTTGGGTGTGATCCTG
Mouse   CAGCTGGAGGGATCCCAGTACGATGCCAAGTCAGATATGTATAGCTTGGGTGTGATCCTG
*** **** ***** * ** ** ******** ******** ************ *****
Canine CTAGAGCTCTTTCAGCCATTTGGAACAGAAATGGAGCGAGTACACATTTTAACAGGTTTA
Human   CTAGAGCTCTTTCAGCCGTTTGGAACAGAAATGGAGCGAGCAGAAGTTCTAACAGGTTTA
Rat     CTCGAGCTCTTCCAGCCATTCGGGACAGAAATGGAGCGAGCAACAGTCCTAACAGGTGTG
Mouse   CTCGAGCTCTTTCAGCCATTCGGGACAGAAATGGAGAGGGCAACAGTCTTAACAGGCGTA
** ******** ***** ** ** *************** * * * * * * * * *
Canine AGAAGTGGTCAGATACCTGACTCCCTCAGTAAGAGGTGTCCCGTGCAAGCCAAGTACATC
Human   AGAACTGGTCAGTTGCCGGAATCCCTCCGTAAAAGGTGTCCAGTGCAAGCCAAGTATATC
Rat     AGGACTGGTCGGATACCAGAGTCCCTCAGTAAAAGGTGTCCAGTGCAAGCCAAGTATATC
Mouse   AGGACTGGTCGGATACCCGAATCCCTCAGTAAAAGGTGTCCGGTGCAAGCCAAGTATATC
** * ***** * * ** ** ****** **** ******** ************** ***
Canine CAGCACTTAACTAGAAGGAATGCATCTCAGAGACCATCTGCTCTTCAGCTGCTGCAAAGT
Human   CAGCACTTAACGAGAAGGAACTCATCGCAGAGACCATCTGCCATTCAGCTGCTGCAGAGT
Rat     CAGCTCCTGACTGGGAGGAACGCGGCCCAGAGACCATCTGCTCTTCAGCTACTGCAGAGC
Mouse   CAGCTCCTAACCGGGAGGAATGTGTCACAGAGACCATCTGCCCTTCAGCTGCTGCAGAGT
* * * **** * ****** * ************** ******* ***** **
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1371
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Canine GAGGGTGACAGAAATCAACATG- - -TTAAAAATGATGAAAGTAACAGCTCATCCATTATC 834
Human   GAAGAGGACAGAGAGCAATGTGGTGTTAAAAATGATGAAAGTAGCAGCTCATCCATTATC 840
Rat     GAAGGGGACAGAAATCAAGGTGGTGTTAAAGATAATGAAAG- - -CAGTTCGTCCATTATC 834
Mouse   GAAGGGGACAGAGACCAAGGTGGTGTTAAAGATAATGAAAG - - - CAGTTCGTCCATTGTC 834
** * ****** * *** ** ***** ** ******* *** ** ****** **
Canine TTCGCCGAGTTCACCTCAGGAAAAGACAAATCCTTAGGAAAATCTGGCATTGAAAATCGG 894
Human   TTTGCTGAGCCCACCCCAGAAAAAGAAAAACGCTTTGGAGAATCTGACACTGAAAATCAG 900
Rat     TTTGCTGAACTCACCCCAGAAAAAGAAAACCCTTTAGCGGAATCTGATGTTAAGAATGAG 894
Mouse   TTTGCTGAACTCACCCCAGAAAAAGAAAAACCTTTTGGGGAGTCTGAGGTTAAAAATGAG 894
** ** ** **** *** ****** ** ** * * **** * * *** *
Canine AATAATAGATTGGTGAACTACAGCACCAGTTTAATCCCCAGAGACACCAGTGAATTTGAA 954
Human   AATAACAAGTCGGTGAAGTACACCACCAATTTAGTCATAAGAGAATCTGGTGAACTTGAG 960
Rat     AATAACAACTTGGTGAGCTACAGGGCCAACTTAGTGATCAGGAGCAGCAGTGAAAGCGAA 954
Mouse   AATAACAACCTGGTGAGCTACACGGCCAACTTAGTGGTCAGGAACAGCAGTGAAAGTGAA 954
***** * ***** **** *** *** * ** ***** **
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M o u s e       MLGGSSVDGERDTDDDAAGAVAAPPAIDFPAEVSDPKYDESDVPAELQVLKEPLQ QPTFP 6 0
Rat        MLGGG S VDGE RDTDDDAAGAVAAP P A I DF P AE V S DPKYDE S DVP AE LQV F K E P LQQP T F P 60
Canine     MLGG S S GA R E R E AEGDGAE AVP AP P A I E F P ADG S DPKYDE S DVP AE LQV L KG P LQQP T F P 60
Human      MQGGNSGVRKREEEGDGAGAVAAPPAIDFPAEGPDPEYDESDVPAEIQVLKEPLQQPTFP 60
* **.* :*: :.*.* **.*****:***: .**:*********:**:* ********
N-terminal heme binding domain
M o u s e       FLVANQLLLVSLLEHLSHVHEPNPLHSKQVFKLLCQTFIKM GLLSSFTCSDEFSSLRLHH 1 2 0
Rat        F L VANQL L L V S L L EHL SHVHE PNP LHS KQV F K L L CQT F I KMGL L S S F TC S DE F S S L R LHH 120
Canine     F AVANQL L L V S L L EHL SHVHE PNP L R S RQV F K L L CQT F I KMGL L S S F TC S DE F S S L R LHH 120
Human      F AVANQL L L V S L L EHL SHVHE PNP L R S RQV F K L L CQT F I KMGL L S S F TC S DE F S S L R LHH 120
* ***********************:*:********************************
Mouse      NRAI THLMRSAKERVRQDPCQDNSYMQKIRSRE IAFEAQTSRYLNEFEELAI LGKGGYGR 180
Rat        NRA I THLMR S AK E RVRQDPCQDNS YMQK I R S R E I A L E AQT S R Y LNE F E E L A I L GKGGYGR 180
Canine     NRA I THLMR S AK E RVRQDPCEDNSHTQK I R S R E I A F E AQT S R Y LNE F E E L AV L GKGGYGR 180
Human      NRA I THLMR S AKE RVRQDPCED I S R I QK I R S R EVA L E AQT S RY LNE F E E L A I L GKGGYGR 180
********************:* * *******:*:***************:********
M o u s e       VYKVRNKLDGQHYAIKKILIKSATKTDCMKVLREVKVLAGLQHPNIVGYHTAWIEHVHVV 2 4 0
Rat        V YKVRNK L DGQHYA I KK I L I K S ATKTDCMKV L R E VKV L AGLQHPN I VGYHTAW I EHVHV L 240
Canine     V YKVRNK L DGQY YA I KK I L I NGATKTDCMKV L R EVKV L AGLQHPN I VGYHTAW I EHVHVT 240
Human      VYKVRNKLDGQYYAIKKI L IKGATKTVCMKVLREVKVLAGLQHPNIVGYHTAWI EHVHVI 240
***********:********:.**** ********************************
M o u s e       QP-Q DRVPIQLPSLEVLSEQEG DRD Q G GVKD NES-SSSIVFAELTPEKEKPFGESEVKNE 2 9 8
Rat        Q P - QDRV P I QL P S L E V L S EHEGDRNQGGVKDNE S - S S S I I F AE L T P E K ENP L A E S DVKNE 298
Canine     HA - QDR I S I QL P S L EV I S DE EGDRNQH - VKNDE S NS S S I I F AE F T S GKDK S L GK S G I ENR 298
Human      QP RADRA A I E L P S L EV L S DQE EDR EQCGVKNDE S S S S S I I F AE P T P EKEKR F G E S DT ENQ 300
:. ** .*:******:*:.* **:* **::** ****:*** *. *:: :.:* :*.
M o u s e       NN NLVSYTANLVVRNSSESESSIELQEDGLTDLSVRPVVRH QLPLG HSSELEGNFTSTDE 3 5 8
Rat        NNNL V S Y R ANL V I R S S S E S E S S I E LQEDGLNE S P L R PVVKHQL P LGHS S DVE GNF T S TDE 358
Canine     NNR L VNY S T S L I P RDT S E F E S P S F LQRNGL ADL P S S S I I EHQL P L RHHS DL E E NF T S TGE 358
H u m a n       NNKSVKYTTNLVIRESGELESTLELQENGLAGLSASSIVEQQLPLRRNSHLEESFTSTEE 3 6 0
**. *.* :.*: *.:.* **. **.:** . .::.:**** : *.:* .**** *
Heme        
Mouse      S SEGNLNLLGQTEVRYHLMLHIQMQLCELSLW DWITERNKRSREYVDEAACPYVMASVAT 418
Rat        S S EDNLN L LGQT E AR YHLMLH I QMQL C E L S LWDWI AE RNKR S RKCVDE AAC P Y VMA S VAT 418
Canine     S S E - NL S L LGQT EVQYHLMLH I QMQL CE L S LWDWI VE RNQRGRQYVDE S ACP Y VMA S VAT 417
H u m a n       SSEENVNFLGQTEAQYHLMLHIQ M QLCELSLW D WIVERNKRGREYVDESACPYVMANVAT 4 2 0
*** *:. :*****.:********************.***:*.*: ***:*******.***
M o u s e       KIFQELVEGVFYIH N M GIVHRDLKPRNIFLHGPDQQVKIGDFGLACADI IQN-AD W TNRN 4 7 7
Rat        K I FQE L V E GV F Y I HNMG I VHRDL K P RN I F LHGPDQQVK I GDF GL ACAD I I QK S ADWTNRN 478
Canine     K I FQE L V E GV F Y I HNMG I VHRDL K P RN I F LHGPDQQVK I GDF GL ACTD I I QKNTDWI GRD 477
H u m a n       KIFQELVEGVFYIH N M GIVHRDLKPRNIFLHGPDQQVKIGDFGLACTDILQKNTD W TNRN 4 80
**********************************************:**:*: :** .*:
Mouse      GKGTR THT S RVGTC L YA S P EQL EG S QYDAK S DMY S LGV I L L E L FQP F GT EME R ATV L TGV 537
Rat        GKGT P THT S RVGTC L YA S P EQL EG S E YDAK S DMY S LGV I L L E L FQP F GT EME R ATV L TGV 538
Canine     GKR P P THT S RVGTC L YA S P EQL EG S DYDAK S DMY S LGV I L L E L FQP F GT EME R VH I L TGL 537
Human      GKRT P THT S RVGTC L YA S P EQL EG S E YDAK S DMY S LGVV L L E L FQP FGT EME R AEV L TGL 540
** . ********************:************:**************. :***:
M o u s e       RTGRIPESLSKRCPVQAKYIQLLTGRNVSQRPSALQLLQSELFQTTGNVNLTLQ M KI IEQ 5 9 7
R a t         RTGRIPESLSKRCPVQAKYIQLLTGRNAAQRPSALQLLQSELFQTTGNVNLTLQ M KIMEQ 5 9 8
Canine     R S GQ I PD S L S KRCPVQAKY I QHL TRRNA S QR P S A LQL LQS E L FQNS GNVNL T L QMK I L EQ 597
Human      RTGQLPESLRKRCPVQAKYIQHLTRRNSSQRPSAIQLLQSELFQNSGNVNLTLQMKI IEQ 600
*:*::*:** *********** ** ** :*****:*********.:***********:**
Canine GAACTTTTCCAAAATTCTGGAAATGTTAACCTCACCCTACAGATGAAAATACTAGAGCAA
Human   GAACTTTTCCAAAATTCTGGAAATGTTAACCTCACCCTACAGATGAAGATAATAGAGCAA
Rat     GAACTGTTCCAAACAACGGGAAATGTTAATCTCACATTGCAGATGAAGATAATGGAGCAA
Mouse   GAGCTTTTTCAAACAACTGGAAATGTTAATCTCACATTGCAGATGAAGATAATAGAACAA
** ** ** **** * *********** ***** * ******** *** * ** ***
Canine GAAAAAGAAATCGAAGAACTAAAGAAGCAGCTGAGTCTCCTTTCTCAGGACAAAGGGGCC
Human   GAAAAAGAAATTGCAGAACTAAAGAAGCAGCTAAACCTCCTTTCTCAAGACAAAGGGGTG
Rat     GAAAAGGAAATTGAAGAATTAAAGAAGCAACTAAGCCTCCTTTCGCAGGACAAAGGGCTG
Mouse   GAGAAGGAAATTGAAGAACTAAAGAAGCAACTAAGCCTCCTTTCTCAGGACAGAGGGCTG
** ** ***** * **** ********** ** * ******** ** **** ****
Canine AAG - GATGATATGAAGGATGGGACTGTGCCCGTCCTGCCTTAA 1893
Human   AGG-GATGACGGAAAGGATGGGGGCGTGGGATGA- - ------- 1 893
R a t      A A G A G A T G A---------------------------------- 1 863
M o u s e    A A G A G A T G A---------------------------------- 1 860
* * *****
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1800
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1860
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(c)
Figure 1: Continued.Advances in Hematology 7
441
K
V
171
172
173
174
175
176
177
178
179
180
181
182
192
193
194
195
196
214
227
228
382
383
384
385
386
387
388
389
392
443
444
445
446
447
448
459
460
461
462
463
ILG GGYGRVYYYAIKEVGQ M QLCELSD D KPRNIFGDFGL
ILGKGGYGRVYHYA IKEVGQMQLCELS DDKPRNI FGDFGL
ILGKGGYGRVYHYA IKEVGQMQLCELS DDKPRNI FGDFGL
GL LGKGGYGRVYYYA
A
A
A
AI K E V G Q M Q L C E L S D D K P R N I F G D F
Human  
Rat    
Mouse  
Canine 
M o u s e       EK EIEELK K Q LSLLS Q D R G L K R----------- 619 
R a t         EK EIEELK K Q LSLLS Q D K G L K R----------- 6 2 0
Canine     E K E I E E L K KQL S L L S QDKGAKDDMKDGTVPV L P 630
H u m a n       EKEIAELKKQLNLLSQ DKGVRDDGKDGGVG--- 6 3 0
**** ******.*****:* :
.  Semi-conserved residues
:  Conserved residues
*  Identical residues
(d)
(e)
Figure1:(a)ExpressionpatternofHRIinhumantissues.RT-PCRproductsfromhumantissueusingHRIspeciﬁcprimerswereseparatedon
a 0.8% agarose gel and visualized by UV. Lanes: 1, liver; 2, kidney; 3, lymph node; 4, spleen. (b) RT-PCR products of canine HRI cDNA from
spleen. 50ng of the resulting cDNA PCR products were separated on an agarose gel (0.8%), stained with ethidium bromide and visualized
by UV. (c) Nucleotide sequence comparison of the canine HRI with human, rat and mouse HRI. Conserved nucleotides between all four
species are denoted with a star. (d) Amino acid sequence alignment of the canine HRI with the mouse, rat, and human HRI. Semi-conserved
residues are designated with a period underneath, conserved residues are shown by semicolon underneath, and the identical residues have
stars underneath them. The residues important for ATP binding are highlighted in gray. (e) Alignment of the residues involved in ATP
binding. Residues important for ATP binding for the human, mouse, rat, and canine HRI are shown. Divergences between the species are
highlighted.
3.2. Expression of Canine HRI Protein by TNT. To express
canine HRI protein, the canine HRI cDNA was cloned into
the pcDNA4 vector for expression by TNT (Figure 2(a)).
After the pcDNA4-HRI was restriction enzyme digested with
NotI, the linearized DNA was incubated with wheat germ
lysate and [35S]-methionine to produce the radiolabeled
canine HRI protein by TNT. The resulting translated prod-
ucts were analyzed on a 4–20% Tris-glycine gel followed by
autoradiography.WefoundthatthecanineHRIproteinyield
was very low using standard TNT reaction conditions (data
not shown). When 0.5mM hemin was included in the TNT
reaction mix, the yield of the canine protein was increased
by ∼5-fold (Figure 2(b)). The enhanced production of HRI
by heme strongly suggests a functional form of canine HRI is
expressed from the cloned canine HRI cDNA.
3.3. Expression of Canine HRI Proteins by Baculovirus Expres-
sion System. Since the majority of canine HRI protein pro-
duced by TNT was found to be misfolded and/or aggregated
and exhibited very low kinase activity, we decided to express
thecanineHRIusinganinsectexpressionsystem.Thecanine
HRI cDNA was inserted into the pFastBac vector and trans-
formed into DH10Bac cells. After conﬁrming that the canine
HRI bacmid DNA contains the canine HRI cDNA insert
by restriction digestion analysis, (Figure 3(a)), the bacmid
DNA was transfected into Sf9 cells to produce recombinant
canine HRI baculovirus. As shown in Figure 3(b),4 8h o u r s
postinfection of Sf9 cells with canine HRI baculovirus, a
band of the expected molecular weight of 72kD correspond-
ing to the canine HRI, was isolated, following expression
and puriﬁcation by His6 aﬃnity chromatography. Since
this 72kD protein bound to nickel aﬃnity matrix and was
speciﬁcally recognized by antibodies against either histidine
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Figure 2: (a) Restriction digestion analysis of the canine-HRI-
containing pcDNA4 plasmid DNA veriﬁes the canine HRI was
inserted into the NotI and EcoRI restriction sites. Digested frag-
ments were separated by agarose gel electrophoresis (0.8%) and
found to have a size of 1925bp. (b) Canine HRI expressed by TNT
using a Promega Wheat Germ Lysate kit. Lane 1 shows the [35S]-
luciferase control and Lane 2 shows the expression of [35S]-canine
HRI. The molecular weight markers are shown to the left of the
autoradiography.
(6xHis) (Figure 3(b)) or HRI (data not shown) epitopes,
we concluded that this was the canine HRI. Similar to the
expression of canine HRI protein by TNT, we found that
canine HRI baculovirus infection resulted in low expression
of the HRI protein if hemin was not included in the cell
culture medium. When hemin at 0.5mM was included,
canine HRI protein expression in the baculovirus expression
system was substantially increased. The human, mouse, rat,
and canine proteins were expressed using the baculovirus
expression system and used in comparison studies.8 Advances in Hematology
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Figure 3: (a) Restriction digestion analysis of the canine HRI-
bacmid DNA veriﬁes the insertion of canine HRI cDNA into the
bacmid DNA with correct orientation. Lane 1, Molecular Weight
markers; Lane 2, pFastBac-canine HRI cDNA. (b) Expression of
mammalian HRIs. HRI, expressed in insect cells, was detected by
Western blot analysis using an aﬃnity puriﬁed mouse monoclonal
antibody against histidine and visualized by enhanced chemilumi-
nescence. Lane 1, canine HRI; Lane 2, mouse HRI; Lane 3, rat HRI;
Lane 4, human HRI.
3.4. Kinase Activity of the Canine HRI Protein. To determine
if the puriﬁed canine HRI protein is enzymatically active,
we performed a kinase activity assay by measuring the
ability of the kinase to phosphorylate a peptide substrate.
As shown in Figure 4, the canine HRI protein was able to
eﬀectivelyphosphorylatethepeptidesubstrate.Toinvestigate
whether the high degree of homology in the ATP-binding
site of canine, human, and rodent HRI results in similar
binding of an ATP-competitive kinase inhibitor, we used a
known human HRI kinase inhibitor, quercetin ([11]a n d
our published data). Quercetin, reported to be an ATP-
competitive kinase inhibitor [11], was tested at various
concentrations from 0.01μM to 100μM against canine,
human, and mouse HRI shown in Figure 5. We found that
similar to human and mouse HRI, canine HRI kinase was
inhibited with IC50 values equal to ∼1μM by quercetin,
demonstrating that among mammalian HRI, ATP-binding
and catalysis are conserved.
3.5. Role of HRI in De Novo Protein Synthesis. To determine
theeﬀectofHRIinhibitionbyquercetinonproteinsynthesis,
we treated canine blood with either 1 or 10μMq u e r c e t i n
for 4 hours in the presence of [35S]-methionine (Figure 6).
Quercetin, at a concentration of 1μM, did not change total
de novo synthesis in canine blood. However, treatment of
canine blood with 10μM quercetin caused a signiﬁcant
increase in de novo protein synthesis compared to the
vehicle control. Because HRI is speciﬁcally expressed in
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Figure 4: Kinase activity of recombinant canine HRI. Kinase
activity of canine HRI was determined by an in-vitro kinase assay
using puriﬁed canine HRI and a kinase peptide substrate. The
experiment was performed in triplicate with the mean ± SEM
shown.
erythroid cells and ∼95% of de novo protein synthesis
in late erythroblasts and reticulocytes is globin protein
[12], the newly synthesized [35S]-methionine labeled protein
measuredis most likely due to de novo hemoglobin synthesis
in erythroid cells. Therefore, we conclude that inhibition
of HRI by the HRI kinase inhibitor is able to increase
hemoglobin synthesis in canine reticulocytes.
4. Discussion
Hemoglobin synthesis in erythroid cells is tightly regulated
by heme, because heme binds to HRI and modulates its
kinase activity. It has been reported that the enzymatically
functional form of HRI is dimeric [7] and remains soluble
devoid of aggregation. Maintaining the dimeric form of HRI
in order to prevent its aggregation makes HRI a diﬃcult
protein to express in large quantities in vitro. We found
that HRI is largely misfolded when expressed by in vitro
TNT, however, the expression of soluble HRI protein can
be improved by supplementing the reaction with heme
(Figure 2). In the HRI protein expression conditions used in
this study, heme primarily plays a critical role by inactivating
newly synthesized HRI by binding to the kinase insert
domain. Consequently, heme addition increased protein
production. In addition, heme addition appears to improve
the yield of soluble protein by preventing newly translated
HRI protein from aggregation. It is conceivable that HRI
incorporates a heme moiety into the N-terminus of the
protein cotranslationally to allow for the proper folding
and assembly of the protein. To improve the protein yield
of the human, mouse, rat, and canine HRI proteins, we
supplemented insect cell culture medium with hemin during
HRI protein expression (Figure 3).
A comparison of the mammalian HRI nucleotide and
aminoacidsequencesrevealsahighdegreeofconservationin
the residues involved in ATP-binding (Figures 1(c), 1(d), and
1(e)). Speciﬁcally, the comparison shows there is only oneAdvances in Hematology 9
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Mouse 6.2 ± 0.1
(d)
Figure 5: Inhibition of HRI kinase activity by quercetin. The kinase activity of the puriﬁed human, mouse and canine HRI proteins was
determined using an in-vitro kinase assay in the presence of various concentrations of quercetin from 0.01μM to 100μM, shown in log
M units. The data are expressed as a percent of activity compared to a vehicle control at 100% at the end of the two hour reaction. All
experiments were performed in duplicate or triplicate with the mean ± SEM represented.
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Figure 6: Eﬀect of HRI inhibition on protein synthesis by quercetin
in canine blood cells. Total protein synthesis in canine blood
was determined by [35S]-methionine incorporation into newly
synthesized protein in the presence of 1 or 10μM quercetin. The
amounts of [35S]-methionine incorporation were compared to a
vehicle control of 1% DMSO and the fold increase with the mean
± S E Mf r o mr e p l i c a t e si ss h o w n .
aminoacidresiduediﬀerencebetweenthehumanandcanine
proteins and only two residues between the mouse and
canine proteins. Additionally, the residues involved in heme-
binding, either in the N-terminal regulatory domain or in
the kinase insert domain, are completely conserved between
the mammalian proteins, implying that the development
and homeostatic regulation of circulatory systems among
mammals is subject to the same evolutionary pressure
(Figure 1(d)). As expected from the high degree of sequence
homology, we have found that the mammalian HRI proteins
show similar ATP aﬃnity with an apparent Km of ∼1-2μM
(data not shown). The high degree of homology in the
catalytic domain is also reﬂected by the similar potency
determined between the mammalian proteins in the ability
of quercetin to inhibit HRI kinase activity (Figure 5).
Normal adult hemoglobin consists of two α- and two
β-globin subunits and its proper assembly is essential for
oxygen transport [5]. The majority (>90%) of actively
translating mRNA in reticulocytes is globin mRNA, and
95% of protein made in reticulocytes is globin protein [12].
Translation of α-a n dβ-globin is tightly controlled by eIF2
and downregulated by HRI. By enhancing translation of
globin by an HRI inhibitor in reticulocytes, the hemoglobin
content of red blood cells is expected to increase causing
an increase in the body’s oxygen-carrying capacity. In this
study, we show that inhibition of HRI by quercetin is able to
increase de novo protein translation in canine reticulocytes
(Figure 6) and also in mouse and rat reticulocytes (data not
shown). Since HRI is predominantly expressed in erythroid
cells [5] and since mature red blood cells do not have the
ability to synthesize protein, we used the [35S]-methionine
incorporation in canine blood as an indirect measure of
hemoglobin synthesis in erythroid cells. Our ﬁnding that
HRI inhibition increases hemoglobin synthesis leads us
to propose that antagonism of HRI may be of potential
therapeutic importance for the treatment of iron-deﬁcient
blood disorders.10 Advances in Hematology
This study also shows that the canine HRI is conserved
not only in the primary sequence of the gene but also
functionally in its role on the regulation of protein synthesis.
Together with the advantage of an ample supply of blood
and similar physiology between canine and human, canine
appears to be a good model species for further elucidation of
the role of HRI protein in its contribution to iron-deﬁcient
anemias and perhaps other hematologic diseases such as β-
thalassemia.
Abbreviations
eIF: Eukaryotic initiation factor
HRI: Heme-regulated inhibitor
ATP: Adenosine tri-phosphate
TNT: Transcription and translation
Quercetin: 3,3 ,4 ,5,7-pentahydroxyﬂavone
TCA: Trichloroacetic acid
bp: Base pair.
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